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Abstract
Non-alcoholic fatty liver disease affects approximately 
one-third of the population worldwide, and its incidence 
continues to increase with the increasing prevalence of 
other metabolic disorders such as type 2 diabetes. As 
non-alcoholic fatty liver disease can progress to liver 
cirrhosis, its treatment is attracting greater attention. 
The pathogenesis of non-alcoholic fatty liver disease is 
closely associated with insulin resistance and dyslipid-
emia, especially hypertriglyceridemia. Increased serum 
levels of free fatty acid and glucose can cause oxida-
tive stress in the liver and peripheral tissue, leading 
to ectopic fat accumulation, especially in the liver. In 
this review, we summarize the mechanism underlying 
the progression of hepatic steatosis to steatohepatitis 
and cirrhosis. We also discuss established drugs that 
are already being used to treat non-alcoholic fatty liver 
disease, in addition to newly discovered agents, with 
respect to their mechanisms of drug action, focusing 
mainly on hepatic insulin resistance. As well, we review 
clinical data that demonstrate the efficacy of these 
drugs, together with improvements in biochemical or 
histological parameters.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: In this review, we summarize the pathogen-
esis underlying the progression of hepatic steatosis to 
steatohepatitis and cirrhosis. We also discuss estab-
lished drugs that are already being used to treat non-
alcoholic fatty liver disease, in addition to newly discov-
ered agents, with respect to their mechanisms of drug 
action, focusing mainly on hepatic insulin resistance. 
As well, we review clinical data that demonstrate the 
efficacy of these drugs, together with improvements in 
biochemical or histological parameters. Furthermore, 
we introduced future treatment option for non-alcoholic 
fatty liver disease.
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INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD), the accumula-
tion of  lipid within hepatocytes, is a common disease[1]. 
The worldwide prevalence of  NAFLD is estimated to 
be 20%-30%[2], although increasing to 57%-74% among 
obese patients[3]. NAFLD refers to a wide spectrum of  
fatty degenerative disorders of  the liver in the absence of  
alcohol intake, ranging from simple steatosis to steatohepa-
titis and cirrhosis[4]. Nonalcoholic steatohepatitis (NASH) 
is histologically characterized by inflammatory cell recruit-
ment. NASH is a significant risk factor for hepatic cirrhosis, 
compared with simple steatosis[5], and 4%-27% of  cases 
of  NASH progress to hepatocellular carcinoma after the 
development of  cirrhosis[6]. In one study, NAFLD was pres-
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ent in 75% of  obese [body mass index (BMI)≥ 30 kg/m2] 
patients, 16% of  non-obese patients, and 34%-74% of  
patients with type 2 diabetes[7]. Another study reported di-
agnoses of  fatty liver in 39% of  obese (BMI ≥ 30 kg/m2) 
patients, 41% of  patients with known type 2 diabetes, and 
32% of  patients with dyslipidemia[8]. Patients with NAFLD 
are not only insulin resistant, but also tend to present with 
alterations in plasma triglyceride (TG) levels[9]. NAFLD 
is strongly associated with metabolic syndrome, especially 
insulin resistance, central obesity, and dyslipidemia. There-
fore, NAFLD is regarded as a difficult to treat component 
of  metabolic syndrome[10]. In this review, we investigate the 
mechanisms of  hepatic fat accumulation, focusing on the 
role of  insulin resistance therein, and review current thera-
peutic options and new candidate drugs for the treatment 
of  NAFLD.
PATHOGENESIS 
Insulin resistance - free fatty acid flux and hyperinsulinemia 
Hepatic steatosis is caused by an imbalance in triglyc-
eride movement through the liver cell. Triglyceride is 
composed of  free fatty acid (FFA) and glycerol. Total 
FFA is derived from three sources, the diet (15%), de novo 
synthesis (26%), and circulating FFA (56%)[11]. A high-
fat diet is known to lead to the development of  hepatic 
steatosis. However, estimates suggest that approximately 
60% of  liver fat is derived from circulating nonesteri-
fied fatty acids (NEFAs) in individuals who eat a normal 
fat-containing diet[11]. Obesity is associated with insulin 
resistance and an elevated leptin level. In particular, in-
creased visceral fat correlates with peripheral and hepatic 
insulin resistance[12,13]. Insulin resistance in skeletal muscle 
and adipose tissue results in increased levels of  NEFAs 
through increased lipid oxidation in adipose tissue (Figure 
1). Accordingly, NEFA flux plays an important role in 
hepatic fat accumulation[14]. An increase in hepatocellular 
diacylglycerol is associated with decreased tyrosine phos-
phorylation of  insulin receptor substrate 2 (IRS-2)[15,16]. 
In turn, the decreased activity of  IRS-2 and PI3K leads 
to increased hepatic glucose production[17]. Hyperinsu-
linemia also arises in response to insulin resistance in adi-
pose tissue, leading not only to downregulation of  IRS-2 
in the liver, but also to a continued increase in the level of  
sterol regulatory element binding protein-1c (SREBP-1c) 
via the insulin signaling pathway involving AKT2, liver X 
receptor (LXR) and mammalian target of  rapamycin[18,19]. 
Elevated levels of  SREBP-1c up-regulate lipogenic gene 
expression, increase fatty acid synthesis, and accelerate 
hepatic fat accumulation[20]. Additionally, overexpression 
of  SREBP-1c represses IRS-2 expression[21]. Glucose-
stimulated lipogenesis is mediated by carbohydrate-
responsive element-binding protein (ChREBP) in the 
liver. Like SREBP-1c, ChREBP increases lipogenesis by 
inducing lipogenic gene expression during consumption 
of  a diet high in carbohydrates[22,23].
Endoplasmic reticulum stress 
The endoplasmic reticulum (ER) is an intracellular organ-
elle that plays an important role in the synthesis, folding, 
and trafficking of  proteins. Cellular nutrient status and 
energy condition highly influence the function of  the 
ER, and dysfunction in the ER causes accumulation of  
unfolded proteins therein, triggering an unfolded pro-
tein response (UPR)[24]. Under stress, such as hypoxia, 
inflammation and energy excess, UPR is characterized by 
adaptive cellular processes of  increased degradation of  
proteins and translational arrest of  protein synthesis to 
restore normal function of  the ER. As well, UPR medi-
ates metabolic and immune responses that aggravate 
insulin resistance[25-27]. Both PKR-like kinase and the 
α-subunit of  translation initiation factor 2 (eIF2α), well-
known ER stress markers, are increased in hepatocytes 
of  ob/ob mice, compared with control mice[26]. Obesity 
causes ER stress that leads to suppression of  insulin sig-
naling through serine phosphorylation of  insulin receptor 
substrate-1 (IRS-1) and activation of  the c-Jun N-terminal 
kinase (JNK) pathway[26]. Among subjects with metabolic 
syndrome, those with NASH showed higher levels phos-
phorylated JNK protein, compared to subjects with sim-
ple hepatic steatosis. Furthermore, subjects with NASH 
did not generate spliced manipulation of  X-box–binding 
protein-1 (sXBP-1), which is a key regulator in ER stress 
in relation to insulin action[24,26]. Additionally, weight 
reduction in obese subjects has been shown to induce 
improvement in ER stress via suppression of  phosphory-
lated JNK and eIF2α in adipose tissue and the liver[28].
Role of oxidative stress - mitochondrial dysfunction 
The two-hit hypothesis is a key concept of  NAFLD 
pathogenesis. In fatty livers, simple hepatic steatosis 
(first hit) sensitizes the liver to inflammatory cytokines 
or oxidative stress (second hit), leading to development 
of  steatohepatitis[29]. Oxidative stress is resulted from a 
serious imbalance between the limited antioxidant de-
fenses and excessive formation of  reactive species such 
as reactive oxygen species (ROS) or reactive nitrogen spe-
cies (RNS)[30]. ROS is an integrated term that describes a 
variety of  species of  free radicals derived from molecu-
lar oxygen, such as superoxide, hydrogen peroxide, and 
hydroxyl[31]. In cells, mitochondria are a major source 
of  ROS generation. The important factor modulating 
mitochondrial ROS generation is the redox state of  the 
respiratory chain[32,33] . FFAs are metabolized via the mito-
chondrial β-oxidation pathway and the tricarboxylic acid 
(TCA) cycle, which generates citrate that in turn inhibits 
glycolysis. As a result, glucose oxidation and glucose up-
take via glucose transporter type 4 (GLUT4) in skeletal 
muscle are reduced[34,35]. To compensate for the exces-
sive fat storage in the liver, increased hepatic FFA uptake 
stimulates hepatic oxidation of  fatty acids in obese indi-
viduals. Mitochondrial FFA oxidation is maintained until 
mitochondrial respiration becomes severely impaired[36,37]. 
However, accelerated β-oxidation not only causes exces-
sive electron flux in the electron transport chain, but also 
leads to increased production of  ROS, and can lead to 
mitochondrial dysfunction[38]. Excessive ROS produc-
tion by mitochondria can lead to oxidative damage to 
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the mitochondrial membrane and DNA and can impair 
mitochondrial metabolic functions[33]. The increase in 
hepatic lipogenesis in NASH results in increased produc-
tion of  malonyl-CoA. Inhibition of  carnitine palmitoyl-
transferase-I (CPT-1) by malonyl-CoA leads to decreased 
entry of  long chain fatty acid into the mitochondria, and 
causes reduced β-oxidation and enhanced triglyceride ac-
cumulation in the liver[38-40]. The nuclear receptor peroxi-
some proliferator-activated receptor α (PPAR-α) plays 
an important role in the transcriptional control of  many 
enzymes involved in mitochondrial fatty acid β-oxidation. 
Peroxisome proliferator-activated receptor-gamma co-
activator (PGC) -1α cooperates with PPAR-α and regu-
lates genes that encode mitochondrial fatty acid oxidation 
enzymes, such as CPT-1 and medium chain acyl-CoA 
dehydrogenase[40]. Previously, a PPAR-α-deficient mouse 
model showed a lack of  hepatic peroxisome proliferation 
and dyslipidemia with obesity and hepatic steatosis[41].
Inflammation and adipokines 
Overall obesity is correlated with NAFLD, and accu-
mulation of  intra-abdominal fat in particular is believed 
to play an important role in the development of  insulin 
resistance[12,13]. Meanwhile, hepatic fat accumulation is 
associated with insulin resistance independent of  intra-
abdominal fat accumulation and overall obesity. Even 
in normal weight subjects, hepatic steatosis has been 
shown to be related to various parameters of  insulin 
resistance, such as basal glucose level or serum FFA 
level[42]. In addition to being a major organ of  triglyceride 
deposition, adipose tissue acts an endocrine organ that 
secretes several hormones[43]. Adipocytes secrete adipo-
nectin and leptin, in addition to the other adipokines, 
such as retinol-binding protein, tumor necrosis factor-α 
(TNF-α), interleukin 6 (IL-6), and plasminogen activator 
inhibitor-1[43]. Adiponectin stimulates phosphorylation 
of  AMP-activated protein kinase (AMPK) and acetyl-
CoA carboxylase (ACC) in the liver and muscles, thereby, 
increasing glucose utilization and fatty-acid oxidation[44]. 
In a previous study, serum adiponectin levels decreased 
with an increases in obesity, in particular increases in 
intra-abdominal fat mass[45,46]. In another study, adiponec-
tin knockout mice fed a high-fat diet exhibited increased 
incidences of  obesity, hyperinsulinemia, and steatohepa-
titis. These experimental data indicate that adiponectin 
may play a key protective role against the progression of  
NASH[47]. Reportedly, adipose tissue in obese individuals 
stimulates a shift in macrophage activation from the al-
802 November 27, 2014|Volume 6|Issue 11|WJH|www.wjgnet.com
Figure 1  Mechanism of hepatic insulin resistance and the key pathway of drug action. Delivery of FFAs to the liver and skeletal muscle is increased in insulin 
resistance conditions, and these are metabolized via mitochondrial β-oxidation. Consequently, hyperglycemia and increased hepatic FFA uptake reduce glucose up-
take and oxidation in skeletal muscle. Diet and exercise are the main treatment strategies for this pathogenesis; insulin sensitizers and MUFA may contribute to reduc-
ing peripheral insulin resistance. Pioglitazone and fenofibrate act on β-oxidation of mitochondria and reduce hepatic steatosis. Accelerated β-oxidation also causes 
increased production of ROS. Vitamin E can reduce oxidative stress. Adipose tissue inflammation of the liver leads to inflammatory activation of hepatic Kupffer cells 
via classic response (M1) and produce inflammatory cytokines. This is also associated with decreased adiponectin levels and promotes hepatic steatohepatitis. Pent-
oxifylline inhibits TNF-α and alleviates steatohepatitis. Hyperglycemia caused by insulin resistance up-regulates lipogenic gene expression, such as SREBP-1c and 
ChREBP, and induces lipogenesis in hepatocytes. Cilostasol may inhibit SREBP-1c. FFA: Free fatty acid; TG: Triglyceride; CPT-Ⅰ: Carnitine palmitoyltransferase-
Ⅰ; ACC: Acetyl-CoA carboxylase; ATGL: Adipose triglyceride lipase; ChREBP: Carbohydrate responsive element binding protein; SREBP-1c: Sterol regulatory ele-
ment binding protein-1c; TCA: Tricarboxylic acid; ROS: Reactive oxygen species; IRS: Insulin receptor substrate; DAG: Diacylglycerol; G-6-P: Glucose 6-phosphate; 
TNF-α: Tumor necrosis factor- α; MUFA: Monosaturated fatty acids; M1: Kupffer cells activated via classic pathway.
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TREATMENT
Life style modification - diet and exercise
Weight loss due to diet and exercise has been demon-
strated to alleviate hepatic steatosis[61]. Body weight re-
duction and exercise are important independent factors 
for improvement of  hepatic steatosis[62]. In obese women, 
hepatic fat content measured by magnetic resonance im-
aging was shown to decrease in response to weight loss 
interventions[63]. Several studies have shown a significant 
reduction in alanine transaminase (ALT) levels and im-
provement in biochemical markers following intervention 
with a calorie-restricted diet combined with exercise[63,64]. 
A few studies have also shown histologic improvement 
with increased exercise and weight reduction[65,66] (Table 
1). Exercise improves insulin sensitivity in skeletal muscle 
via GLUT4 expression and increases glucose utilization. 
Thus, exercise decreases levels of  serum glucose and in-
sulin[67]. An improvement in hyperinsulinemia can result 
in decreased liver fat mass, because hyperinsulinemia 
stimulates hepatic steatosis via the SREBP-1c pathway[19]. 
In particular, NAFLD patients with metabolic syndrome 
show a great improvement in hepatic steatosis after 
weight loss[68].
Insulin sensitizer-thiazolidinedione, metformin
Thiazolidinedione: Thiazolidinediones (TZDs) are in-
sulin-sensitizing agents that have been shown to improve 
not only hepatic steatosis, but also whole body insulin 
resistance[69]. Improvements in insulin resistance and his-
tologic and biochemical parameters were reported with 
TZD treatment[70-74]. Rosiglitazone is one TZD and is as-
ternative response (M2) to the classic response (M1), and 
these classically activated macrophages (CAMs) secrete a 
variety of  inflammatory cytokines, such as TNF-α, IL-6, 
and NO[48]. Additionally, studies showed that inflamma-
tory activation of  hepatic Kupffer cells in ob/ob mice 
promotes hepatotoxicity, resulting in hepatic insulin resis-
tance and steatohepatitis[49,50]. Thus, increases in TNF-α 
and IL-6 in obese subjects may play an important role in 
insulin resistance and hepatic steatosis[51,52].
Gut-microbial alternation and TLRs stimulation
As mentioned above, obesity is often associated with 
NASH and systemic inflammation characterized increases 
in inflammatory cytokine levels. Obesity also can cause in-
creased intestinal mucosa permeability and endotoxin lev-
els in portal circulation that can contribute to hepatocel-
lular damage[53,54]. Kupffer cells in the liver play a key role 
in clearing endotoxin and are activated through Toll like 
receptor 2,3,4 and 9 signaling in the presence of  endotox-
in. In particular, activation of  Toll like receptor4 (TLR4) is 
reportedly associated with stimulation of  lipopolysaccha-
ride (LPS)[55-57]. Previously, animal model studies showed 
that TLRs 2, 4 and 9 may contribute to the pathogenesis 
of  NAFLD[55,58]. Activated Kupffer cells induce expres-
sion of  pro-inflammatory cytokines, such TNF-α, IL-6, 
IL-18 and IL-12 as well as anti-inflammatory cytokines[59]. 
TLRs including TLRs 2,4 and 9 are activated via a MyD88 
dependent pathway. This pathway consists of  the activa-
tion of  serine kinase IL-1R-associated kinase and TBF-
receptor-associated factor 6 and is involved in the activa-
tion of  the transcription factor NF-κB, which is related to 
inflammatory cytokine production[60].
  Study Treatment group Control group No. Study design Duration (mo) Histology Liver enzymes US
  Life style modification
     Huang et al[66] Diet -   12 Open label 12 Improved - -
     Ueno et al[65] Diet/Exercise Control   15 Open label   3 Improved Improved -
  Pioglitazone (insulin sensitizer)
     Promrat et al[71] Pioglitazone -   18 Open label 12 Improved Improved -
     Belfort et al[72] Pioglitazone and Diet Placebo   55 RCT   6 Improved Improved -
     Aithal et al[73] Pioglitazone and diet/Exercise Placebo   74 RCT 12 Improved Improved -
     Sanyal et al[74] Pioglitazone Placebo      163 RCT 24 Improved Improved -
  Metformin (insulin sensitizer)
     Garinis et al[100] Metformin and Diet Diet   50 RCT   6 - - Improved
     Haukeland et al[103] Metformin Placebo   48 RCT   6 - - -
     Uygun et al[101] Metformin and Diet Control   50 Open label   6 - - Improved
     Bugianes et al[99] Metformin Diet   53 RCT 12 Improved Improved -
     Bugianes et al[99] Metformin Vitamin E   57 RCT 12 - Improved -
  Vitamin E (antioxidant)
     Bugianesi et al[99] Vitemin E Diet   55 RCT 12 - - -
     Sanyal et al[74] Vitamin E Placebo 167 RCT 24 Improved Improved
     Vajro et al[109] Vitamin E Diet   25 RCT   6 - - -
  Other drugs
     Sanjay et al[112] Pentoxifylline -   18 Open label   6 - Improved -
    Yoneda et al[127] Ezetimibe -   10 Open label   6 Improved Improved
    Vasilios et al[118] Statin Control      437 Open label 36 - Improved -
    Lindor et al[130] UDCA Placebo      166 RCT 48 - - -
    Capani et al[138] PUFA Control   42 RCT 12 - Improved Improved
Table 1  Treatment outcomes of variable regimens
No.: Number; US: Ultrasonography; RCT: Randomized controlled trial.
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sociated with an increased risk of  myocardial infarction 
and cardiovascular death[75]. Meanwhile, pioglitazone is re-
garded as safe in regards to cardiovascular outcomes and 
is not associated with increased cardiovascular risk[76,77]. In 
patients with type 2 diabetes, pioglitazone has been rec-
ommended for the treatment of  steatohepatitis proven 
by liver biopsy; however, its role in non-diabetic patients 
has not been established. The American Association for 
the Study of  Liver Disease (AASLD) introduced piogli-
tazone as a first-line treatment of  NAFLD in patients 
with type 2 diabetes[78]. TZDs increase glucose utilization 
of  peripheral tissue and improve whole body insulin sen-
sitivity as measured by the hyperinsulinemic euglycemic 
clamp technique, in patients with type 2 diabetes. More-
over, serum adiponectin levels increase and serum insulin 
levels decreases after treatment with pioglitazone[79,80]. An 
increase in serum adiponectin contributes to alleviation 
of  hepatic steatosis and improves hepatic and peripheral 
insulin resistance[79]. As mentioned above, adiponectin 
increases lipid oxidation of  FFA by ACC phosphoryla-
tion in the liver[44], and promotes the activation of  anti-
inflammatory M2 macrophages rather than M1 mac-
rophages[81]. Obesity is closely related to an increase in 
NAFLD risk[82]. Increased levels of  inflammatory adipose 
tissue macrophages (ATMs) and their secreted cytokines 
in a mouse model were shown to be related to systemic 
insulin resistance, which is associated with NAFLD de-
velopment[15,83]. According to previous studies, ATMs are 
increased in obese subjects[84], and pioglitazone treatment 
results in not only a decrease in ATM content, but also in 
the inflammatory markers, TNF-α, IL-6, and inducible 
nitric oxide synthase (iNOS)[85,86]. TZDs also promote the 
alternative activation of  monocytes into macrophages 
with anti-inflammatory properties, as opposed to the pro-
inflammatory phenotype[87]. Although the pathogenesis 
of  NAFLD development is closely related to obesity, 
the distribution of  fat is more important than overall 
obesity. Excessive visceral fat accumulation plays an im-
portant role in the development of  insulin resistance and 
NAFLD by acting as a source of  FFA[12]. Pioglitazone is 
strongly associated with fat redistribution, increases in 
subcutaneous fat area decreases in visceral fat area (vis-
ceral to subcutaneous fat ratio)[88]. Another study showed 
that the ratio of  visceral fat thickness to subcutaneous 
fat thickness decreases after pioglitazone treatment and 
is correlated with a change in high sensitivity C-reactive 
protein levels[89]. TZD treatment results revealed a de-
crease in serum FFA levels, which in turn reduced FFA 
supply to the liver and led to a decrease in hepatic triglyc-
eride content[90]. Recent studies have focused on the role 
of  sirtuin-6 (SIRT-6) in the glucose and lipid metabolism 
associated with TZDs. TZD treatment reduced hepatic 
fat accumulation and increased expression of  SIRT-6 and 
PGC1-α in rat livers[91]. Also, liver-specific SIRT-6 knock-
out mice exhibited fatty liver formation[92], leading to 
NASH[93].
Metformin: Metformin improves insulin resistance and 
hyperinsulinemia by increasing peripheral glucose uptake 
and decreasing hepatic gluconeogenesis[94]. Metformin 
activates AMP kinase via a LKB-1 dependent mechanism 
in skeletal muscle. Also it can activate AMPK by stimu-
lating AMP accumulation in hepatocytes. The increase 
in AMP interferes with glucagon action and decreases 
cAMP levels, leading to decreased production of  hepatic 
glucose[95,96]. Activation of  AMPK results in decreased 
hepatic triglyceride synthesis and increased fatty acid 
oxidation[97], as well as attenuated hepatic steatosis due to 
decreased SREBP-1c activity[98]. A randomized controlled 
trial showed that subjects treated with metformin exhibit 
significant improvement in ALT levels, compared with those 
who were on a restricted diet or were treated with vitamin 
E, as well as improvements in histology after a 12 mo of  
treatment[99,100]. Many studies have shown that metformin 
treatment normalizes transaminase levels and decreases 
hepatic steatosis as determined by follow-up ultrasound; 
nevertheless, histologic data remain limited[100-103]. As 
NASH is closely associated with development of  HCC 
and liver fibrosis, metformin may be limited in the reduc-
tion of  these severe outcomes, including mortality[104].
Antioxidant - vitamin E (α-tocopherol), pentoxifylline
As mentioned above, oxidative stress contributes to the 
progression of  NASH from simple hepatic steatosis. 
A recent study reported that subjects who were treated 
with vitamin E (α-tocopherol) showed improvement in 
hepatic steatosis and serum aminotransferase levels com-
pared to a placebo group[74]. Vitamin E (α-tocopherol) 
has been used to treat non-diabetic NASH patients di-
agnosed by liver biopsy[78]. Meta-analyses of  vitamin E 
have revealed an increase in all-cause mortality with high 
dose (≥ 400 IU/d) vitamin E supplement use, especially 
in subjects with chronic disease or at high risk for cardio-
vascular disease events, such as type 2 diabetes. However, 
these results are uncertain in healthy subjects[105,106]. Two 
pilot studies reported improved ALT levels with vitamin 
E treatment[107,108]. However, two randomized controlled 
trials failed to show the efficacy of  vitamin E treatment 
in NAFLD[109,110]. Pentoxifylline, a TNF-α inhibitor, has 
also been considered for the treatment of  hepatic ste-
atosis, since it plays an important role in the progression 
of  simple hepatic steatosis to steatohepatitis. In previous 
studies, administration of  pentoxifylline generated im-
provements in biochemical markers, such as aminotrans-
ferase and Homa-IR, in patients with NASH[111,112]. Nev-
ertheless, further study is needed to prove the efficacy of  
pentoxifylline with respect to histologic improvement of  
NAFLD.
Lipid-lowering agents - fibrates, ezetimibe and statins
Hypertriglyceridemia is a major component of  metabolic 
syndrome and is strongly associated with NAFLD. In-
creased FFA delivery to the liver causes accumulation of  
hepatic fat[9]. Many different lipid-lowering agents have 
been investigated for the treatment of  NAFLD. Patients 
treated with gemfibrozil, one type of  fibrate, showed 
decreased ALT levels, compared to the control group[113]. 
However, clofibrate did not show a beneficial effect on 
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NAFLD[114]. PPAR-α modulates not only FFA transport 
and β-oxidation to decrease triglyceride in hepatocytes, 
but also glucose and amino acid metabolism in liver and 
skeletal muscle. PPAR-α activation is involved in lipopro-
tein metabolism by increasing lipolysis, thus reducing the 
production of  triglyceride-rich particles[115]. Fenofibrate 
increased levels of  PPAR-α and decreased hepatic steato-
sis in an APOE2KI mouse model that represented diet-
induced NASH[116]. A prospective study using atorvastatin 
reported significant reductions in serum transaminase 
level[117,118]. Atorvastatin induces hepatic low-density lipo-
protein receptor-related protein 1 (LRP-1) that plays an 
important role in clearance of  circulating triglyceride in 
the liver[119]. In disposal of  chylomicron in hepatocytes, 
interaction of  LRP-1 receptors and ApoE play important 
roles[120]. Thus, ApoE-deficient mice showed develop-
ment of  hepatic steatosis even when they were fed a nor-
mal chow-diet. Accordingly, ApoE may play a key role in 
intracellular metabolism and control of  VLDL produc-
tion by hepatocytes[121]. Statins are very important drugs 
to treat dyslipidemia in subjects with both insulin resis-
tance and NAFLD. However, there is continued concern 
about the use of  statins in subjects with established liver 
disease. According to several randomized controlled stud-
ies and retrospective studies, statin rarely induces serious 
liver injury[122-125]. Ezetimibe, a potent inhibitor of  choles-
terol absorption, has been reported to improve hepatic 
steatosis in obese Zucker fatty rats[126]. In a randomized 
controlled study, six months of  treatment with ezetimibe 
led to improvements in serum ALT levels and histologic 
observations[127,128].
Ursodeoxycholic acid
Ursodeoxycholic acid (UDCA) is widely used in subjects 
with abnormal liver function. Several studies have in-
vestigated the efficacy of  UDCA as a treatment drug of  
NAFLD, reporting that UDCA treatment attenuated he-
patic steatosis, including histologic improvement[114,129,130]. 
However, in a placebo controlled, randomized control 
trial, UDCA exhibited limited efficacy in histologic im-
provement in subjects with NASH and improvements 
in liver enzyme did not differ in the UDCA group, com-
pared to the placebo group[130]. Accordingly, AASLD does 
not recommend UDCA for the treatment of  NAFLD[78].
Other treatment options - future candidates
Cilostazol: SREBP-1c is a key regulator of  lipogenic 
gene expression in hepatocytes. Recent data have shown 
that cilostazol, a selective type Ⅲ phosphodiesterase in-
hibitor, inhibits SREBP-1c expression via the suppression 
of  LXR and Sp1 activity[131]. Cilostazol also decreases 
serum triglyceride levels by increasing lipoprotein lipase 
(LPL) activity in STZ-induced diabetic rats[132]. Also, ex-
perimental data show that cilostazol stimulates LRP1 pro-
moter activity in hepatocytes, leading to increased hepatic 
LRP1 expression[133]. In a study that used two experimen-
tal NAFLD models, both high-fat/high-calorie (HF/HC) 
diet mice and the choline-deficient/L-amino acid-defined 
(CDAA) diet mice, cilostazol generated improvement in 
hepatic steatosis in both mice models[134]. Cilostazol ex-
hibits the potential for improvement of  hepatic steatosis, 
and further data on its role in NAFLD are needed. 
Polyunsaturated fatty acids and monounsaturated 
fatty acids: Polyunsaturated fatty acids (PUFAs) are 
found primarily in safflower, corn, soybean, cottonseed, 
sesame, and sunflower oils. Omega-3 fatty acids are rep-
resentative of  PUFA. A marked increase in long-chain 
PUFA n-6/n-3 ratio is observed in NAFLD patients and 
is associated with increased production of  pro-inflamma-
tory eicosanoids and dysregulation of  liver and adipose 
tissue function[135]. PPAR-α activity is impaired in condi-
tions in which levels of  circulating n-3 PUFA are de-
creased and the n-6/n-3 fatty acid ratio is increased[136,137]. 
Treatment with n-3 PUFA was shown to improve bio-
chemical parameters and alleviated hepatic steatosis by 
ultrasound follow-up[138,139]. Monounsaturated fatty ac-
ids (MUFAs) are comprised in olive oil. In a rat model, 
supplementation with MUFA resulted in improved insulin 
sensitivity, compared to rats fed a saturated fatty acid (SFA) 
diet. Additionally, GLUT4 translocation in skeletal muscle 
was decreased in rats fed a SFA diet, but not in those fed 
a MUFA diet. Increased GLUT4 translocation is related 
to an improvement in insulin sensitivity[140]. In obese rats, 
MUFA diet attenuated hepatic steatosis and altered he-
patic fatty acid levels[141]. The beneficial effects of  dietary 
MUFA in NAFLD patients should be investigated.
GLP-1 analogue: Exenatide is the synthetic form of  
exendin4 and it stimulates endogenous insulin secretion, 
leading to decreases in blood glucose. In one animal study, 
treatment of  exendin4 resulted in a decrease of  hepatic 
fat content, as well as reduction of  fatty acid synthesis, in 
the liver of  ob/ob mice[142]. In patients with type 2 dia-
betes, an exenatide treatment group showed greater im-
provements in liver enzymes, attenuating hepatic steatosis, 
than the metformin treatment group. However, this study 
had limitations of  a lack of  histologic confirmation of  the 
liver[143]. To prove the efficacy of  glucagon like peptide-1 
(GLP-1) analogue in treatment of  NAFLD, randomized 
controlled trials over a longer period are required.
MK615: MK615 is extracted from Japanese apricots, and 
can suppress the production of  inflammatory cytokines 
such as TNF-α and IL-6 by inactivating NF-κB[144,145]. 
MK615 is regarded as a hepatoprotective agent, as it has 
been shown that a MK615 treatment group exhibited 
greater decreases in liver enzyme levels, compared with 
control groups. In rat models, MK615 treatment mice 
showed more improved liver histology than control 
mice[146]. Thus, further studies are required to clarify the 
effects of  MK615 in subjects with NAFLD.
CONCLUSION
NAFLD is a common disease that can progress to liver 
cirrhosis. Moreover, NAFLD is strongly associated with 
type 2 diabetes and insulin resistance. NAFLD is the 
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result of  complex interactions among diet, metabolic 
components, adipose tissue inflammation, and mitochon-
drial dysfunction. The pathogenesis of  hepatic steatosis 
has not yet been fully determined. In this review, we 
outlined previously known mechanisms of  NAFLD, 
as well as introduced new mechanisms that have been 
recently discovered. Above all, we reviewed the mecha-
nisms of  drugs matched to the pathogenesis of  NAFLD. 
Furthermore, we introduced future treatment option for 
NAFLD. TZDs play a key role in restoring insulin sensi-
tivity and decreasing adipose tissue inflammation, gener-
ating histologic improvements in hepatic steatohepatitis. 
Pioglitazone can be used to treat NASH in patients with 
type 2 diabetes with biopsy-proven NAFLD; meanwhile, 
non-diabetic patients can be treated with vitamin E. Met-
formin is a well-known insulin sensitizer; however, fur-
ther study is needed to prove histologic improvements in 
patients with NAFLD. Additionally, the cholesterol-low-
ering agent ezetimibe has also shown histologic improve-
ments. Cilostazol acts on SREBP-1c and can improve 
dyslipidemia; however, further research is needed to 
clarify the relationship between NAFLD and cilostazol. 
Finally, there is an outstanding need for effective preven-
tive and therapeutic regimens to overcome NAFLD.
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